Main Article Content
Objectives: Primary malignant liver tumours account for more than 1% of all paediatric malignancies, with the most common form being hepatoblastomas (HB). Such malignancies among Arab populations have rarely been addressed in the literature. Using data from Oman’s sole national referral centre for childhood solid malignancies, this study aimed to present the nationwide Omani experience with HB over the past 21 years. Methods:This retrospective study reviewed the medical records of all children with HB who were managed in the Royal Hospital, Muscat, Oman, between January 1991 and April 2012. Clinical, radiological and laboratory characteristics were examined as well as treatments and outcomes. Results: During the study period, 15 patients with HB were treated. Of these, 10 have survived to date. Nine of the survivors were no longer receiving treatment and one patient still had the disease but was in a stable condition. Of the remaining five patients, three did not survive and two were lost to follow-up. The survival rate among patients who completed therapy was 91%. Conclusion: HB has an excellent prognosis in Oman. The main obstacle to improving outcomes among Omani patients is non-compliance with therapy.
Hepatoblastoma Neoadjuvant Therapy Hepatic Cancer Oman.
How to Cite
Rabah, F., El-Banna, N., Bhuyan, D., Al-Ghaithi, I., Al-Hinai, M., Al-Sabahi, A., Al-Mashaikhi, N., & Beshlawi, I. (2015). Hepatoblastomas in Oman : Unveiling success. Sultan Qaboos University Medical Journal [SQUMJ], 15(1), 85–90. Retrieved from https://journals.squ.edu.om/index.php/squmj/article/view/1994